Latest News for: usfda

Edit

USFDA clears Dr Reddy’s licence application for biosimilar to Orencia

Business Line 21 Feb 2026
The proposed drug is intended for the treatment of arthritis ....
Edit

USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB

The Times of India 21 Feb 2026
USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB Swati Bharadwaj Hyderabad ... A pivotal Phase 3 study (AB-01-004) comparing the efficacy and safety of DRL_AB with Orencia is currently underway. .
Edit

Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launch

The Times of India 20 Feb 2026
Zydus Lifesciences is in focus after receiving USFDA clearance with zero ...
Edit

Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable ...

Business Wire 20 Feb 2026
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Abatacept--Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept ... .
Edit

Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Pharmiweb 20 Feb 2026
Following the submission in December 2025, USFDA has accepted Dr ... Reddy’s”), today announced that the US Food and Drug Administration (USFDA) has accepted for review, its 351 (k) Biologics License ...
Edit

DifGen Pharmaceuticals LLC Receives USFDA Approval for Fluorometholone Ophthalmic Suspension, 0.1% - Expanding Its Complex Generic Portfolio

PR Newswire 12 Feb 2026
Food and Drug Administration (USFDA) for its Fluorometholone Ophthalmic Suspension, 0.1% - a complex generic formulation used to treat eye inflammation. This is only the second generic USFDA approval of this complex suspension product.
Edit

Zydus’ Desidustat gets USFDA orphan drug status for sickle cell disease

The Economic Times 06 Feb 2026
Zydus Lifesciences announced a significant development today ... .
Edit

Natco Pharma gets USFDA nod for cancer generic drug

Business Line 03 Feb 2026
Natco’s Erdafitinib is approved for ...
×